1. Within your trust how many intra-vitreal injections/implants of each of the following drugs have been used in the four-month period from January to April 2020:
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
2. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used from January to April 2020, for each of the following conditions:
Wet Age Related Macular Degeneration (wAMD)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Diabetic Macular Oedema (DMO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Retinal Vein Occlusion – Central (CRVO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Retinal Vein Occlusion – Branch (BRVO)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)
Abicipar pegol
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab
